Allergy Immunotherapy Market Poised for Strong Expansion as Biopharma Leaders Boost R&D and Pipeline Investments

The global Allergy Immunotherapy Market is poised for substantial growth as allergic conditions continue to surge in prevalence and patients increasingly seek long-term, disease-modifying treatments. According to Vantage Market Research, the market was valued at approximately USD 1.92 billion in 2024 and is projected to reach USD 4.90 billion by 2035, growing at a CAGR of 8.95% from 2025 to 2035.The expansion reflects broader adoption of both subcutaneous and sublingual immunotherapy, and growing access to allergy care across regions.

Key Takeaways

1. The Allergy Immunotherapy market is expected to more than double in size by 2035, reflecting strong, sustained demand for long-term allergy treatments.
2. Subcutaneous Immunotherapy (SCIT) remains a dominant delivery format, but Sublingual Immunotherapy (SLIT) is gaining ground due to convenience and patient preference.
3. The allergy type mix includes allergic rhinitis, asthma, food allergy, venom allergy, and others — with allergic rhinitis continuing to drive the largest share.
4. Distribution channels are evolving, with hospital pharmacies, retail pharmacies, and increasingly, online pharmacies being used for immunotherapy products.
5. Regionally, Europe currently holds the largest share, while Asia Pacific is projected to show the fastest growth through 2035.
6. Key challenges remain in patient compliance, regulatory complexity, and awareness but opportunities lie in novel biologic therapies and expanding geographic access.

Key Market Trends & Insights

1. Increasing prevalence of allergic diseases including rhinitis, asthma, and food allergies is a major driver for immunotherapy demand, as more patients seek long-term solutions.
2. Technological innovation continues to reshape the market: biologics, recombinant allergens, and component-resolved therapy are improving the safety and efficacy of allergy immunotherapies.
3. Patient preference is shifting toward less-invasive options: sublingual (under-the-tongue) immunotherapy is gaining traction, especially among pediatric and adult patients who dislike injections.
4. Healthcare systems and payers are recognizing immunotherapy’s value: by reducing symptomatic medication use and improving quality of life, these therapies may lead to lower long-term costs.
5. Digital tools (e.g., mobile adherence apps, remote monitoring) are emerging to support therapy compliance, a key challenge in multi-year immunotherapy regimens.
6. Geographically, rising allergy burden and access to care in Asia Pacific make the region a high-growth opportunity, supported by improving infrastructure and reimbursement.

Market Size & Forecast

1. 2024: USD 1.92 billion
2. 2035 Forecast: USD 4.90 billion.
3. CAGR (2025–2035): 8.95%.

The allergy immunotherapy market features a mix of established pharmaceutical players and niche biotech innovators. Key characteristics include:

1. Moderate concentration: Major companies like ALK-Abelló, Stallergenes Greer, Allergy Therapeutics, HAL Allergy, DBV Technologies and others dominate, but smaller firms pushing biologics and novel delivery are also active.
2. Long-term treatment model: Immunotherapy often requires multi-year administration, which creates sustained patient engagement and recurring revenue.
3. Regulatory complexity: Immunotherapy products whether allergen extracts, recombinant allergens, or biologics must meet safety, standardization, and potency criteria, leading to rigorous development and oversight.
4. Patient compliance challenge: Because therapy spans years, adherence is a key obstacle. Manufacturers and providers increasingly offer tools to improve persistence.
5. Geographic scaling: While Europe is currently dominant, players are expanding into Asia Pacific, Latin America, and other regions, capitalising on growing disease prevalence and improving healthcare access.
6. Innovation potential: Biologics, component-resolved immunotherapy, and personalized allergen profiles offer future differentiation and growth.

Type Insights

The Allergy Immunotherapy Market is segmented by type into Subcutaneous Immunotherapy (SCIT) and Sublingual Immunotherapy (SLIT). SCIT remains the traditional and widely adopted option due to its proven long-term efficacy and broader allergen coverage, especially for patients with complex allergy profiles. SLIT, available as tablets or drops, is gaining rapid traction because of its superior safety profile, home-based administration, and improved patient compliance. The shift toward non-invasive treatments, along with growing regulatory approvals for SLIT tablets, continues to reshape market dynamics.

Allergy Type Insights

Segmentation by allergy type includes Allergic Rhinitis, Allergic Asthma, Food Allergy, and Others. Allergic rhinitis dominates the segment as rising pollution levels, lifestyle changes, and seasonal variations increase global prevalence. Allergic asthma follows due to the growing burden of respiratory diseases. Food allergies are emerging as a fast-growing segment with rising diagnostic awareness and pediatric sensitizations. Increasing R&D for specific allergen extracts and standardized formulations supports greater adoption across all categories, with precision-based allergen immunotherapies gaining high clinical acceptance.

Distribution Channel Insights

The market is divided into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Hospital pharmacies lead due to the need for specialist supervision and frequent clinical visits associated with SCIT treatments. Retail pharmacies play a vital role in dispensing SLIT products and maintenance therapies. Online pharmacies are growing quickly, driven by digital healthcare adoption, improved accessibility, and attractive pricing. The expansion of tele-allergy services and remote treatment monitoring further supports online channels, especially in regions with limited specialist availability.

Regional Insights

North America Market Trends

In North America, the allergy immunotherapy market is well-established and continues to grow, driven by strong healthcare infrastructure, high allergy awareness, and broad adoption of SCIT and SLIT. Regulatory support, insurance reimbursement, and a mature patient base support uptake. The U.S. in particular is a key market, with major players offering both traditional and novel immunotherapy options.

Europe Market Trends

Europe is currently the largest regional market for allergy immunotherapy, according to Vantage Market Research. Key drivers include widespread allergy prevalence, favorable reimbursement policies, and long experience with immunotherapy. European allergy specialists and long-term treatment infrastructure help support both SCIT and SLIT adoption. Regulatory harmonization and patient education further promote market expansion.

Asia Pacific Market Trends

Asia Pacific is forecast to be the fastest-growing region over the next decade. Rising allergy incidence, increasing healthcare spending, growing access to allergy care, and expanding immunotherapy infrastructure are key factors. Local players are entering the market, and international companies are scaling operations. Urbanization, environmental pollution, and rising awareness of allergic disease also contribute to growth.

Latin America Market Trends

In Latin America, allergy immunotherapy is emerging as a growth opportunity. Growing urbanization, rising healthcare access, and increasing diagnosis of allergic conditions support expansion. While historically penetration has been lower compared to North America and Europe, partnerships, cost-effective SLIT options, and improved distribution channels are driving interest in immunotherapy across key Latin American countries.

Middle East & Africa Market Trends

The Middle East & Africa (MEA) region is at a nascent stage for allergy immunotherapy, but promising growth is on the horizon. Increasing healthcare infrastructure investment, growing awareness of allergic diseases, and rising middle-class populations are accelerating demand. Regulatory challenges and limited specialist access remain, but expanding hospital networks and partnerships with global immunotherapy players are likely to drive future uptake.

Top Key Players in the Allergy Immunotherapy Market

1. Merck KGaA
2. Jubilant Pharma (Hollister Allergy)
3. Leti Pharma
4. Stallergenes Greer
5. ALK-Abello A/S
6. Allergy Therapeutics
7. Anergis SA
8. ASIT Biotech
9. DBV Technologies
10. HAL Allergy Group
11. Aimmune Therapeutics
12. Arrayit Corporation
13. Biomay AG

These companies compete by expanding product pipelines (extracts, biologics), geographic footprint, and patient access. Some are focusing on pediatric indications (food allergy), while others are innovating in delivery (SLIT, oral) and regulatory differentiation.

Recent Developments

1. In January 2025, Stallergenes Greer announced that the European Commission approved the extension of indication for Palforzia® (peanut oral immunotherapy) in toddlers aged 1–3 years with confirmed peanut allergy.
2. In December 2024, the European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) gave a positive opinion on extending Palforzia® to toddlers, paving the way for broader use in early childhood.

Report Scope

The Allergy Immunotherapy Market Report provides an in-depth assessment of global market performance, including revenue analysis for 2024 and forecast projections through 2035. It covers CAGR estimates for 2025–2035 and evaluates key growth drivers, restraints, opportunities, and challenges shaping demand for SCIT and SLIT therapies. The report outlines detailed segmentation by type, allergy type, and distribution channel, along with comprehensive regional insights across major markets. It also analyzes competitive landscapes, key company strategies, and recent developments influencing long-term market expansion.

Market Dynamics

Driver

A key driver of market growth is the rising global prevalence of allergic diseases, including allergic rhinitis, asthma, food allergies, and venom sensitivities. Increased urbanization, environmental pollution, changing lifestyles, and heightened patient and physician awareness are boosting demand for disease-modifying therapies. Immunotherapy offers long-term benefits by addressing allergy etiology rather than merely treating symptoms, making it a compelling choice for both patients and healthcare systems.

Restraint

High costs and long treatment duration remain significant restraints. Allergy immunotherapy typically requires multiple years of dosing (especially SCIT), which can be burdensome for patients in terms of time commitment, potential adverse reactions, and financial cost. Reimbursement can be inconsistent across regions, and patient adherence over long courses of therapy is often suboptimal, reducing overall market potential.

Opportunity

There is substantial opportunity in emerging markets, particularly in Asia Pacific and Latin America, where allergy prevalence is rising and access to immunotherapy is expanding. Novel delivery formats such as SLIT, oral immunotherapy, and biologics are also opening doors to new patient populations for example, pediatric food allergy or needle-averse adult patients. Digital adherence support and remote care can further enhance patient retention and market penetration.

Challenges

Major challenges include ensuring patient compliance over extended treatment periods, managing regulatory complexities across different regions, and standardizing allergen extract quality. The risk of adverse reactions (especially in SCIT) demands careful clinical monitoring. Additionally, scaling up immunotherapy infrastructure (clinics, trained personnel) in underdeveloped regions will require significant investment and education.

Report Segmentation

According to Vantage Market Research, the market is segmented by:

1. By Type: Subcutaneous Immunotherapy; Sublingual Immunotherapy
2. By Allergy Type: Allergic Rhinitis; Allergic Asthma; Food Allergy; Atopic Dermatitis; Other Allergy Types
3. By Distribution Channel: Institutional Sales; Retail Sales
4. By Region: North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Frequently Asked Questions

Q1: What was the allergy immunotherapy market size in 2024?

A1: The global allergy immunotherapy market was valued at USD 1.92 billion in 2024, per Vantage Market Research.

Q2: What is the projected market size in 2035 and its CAGR?

A2: The market is forecast to reach USD 4.90 billion by 2035, with a CAGR of 8.95% from 2025 to 2035.

Q3: Which region leads the market, and which is expected to grow the fastest?

A3: Europe currently leads in market share, while Asia Pacific is projected to grow at the fastest rate through 2035.

Q4: What are the key treatment types in this market?

A4: The primary treatment types are Subcutaneous Immunotherapy (SCIT), Sublingual Immunotherapy (SLIT), and Oral / Specific Immunotherapy (OIT/SIT).

Q5: What recent regulatory milestone has occurred?

A5: In January 2025, Stallergenes Greer obtained EU-wide approval for Palforzia® indicated for toddlers (1–3 years) with peanut allergy making it the first oral immunotherapy for that age group in Europe.